Show Hide image

ImmunoCellular develops new ICT-107 manufacturing method

Dendritic cell-based vaccine for treatment of glioblastoma multiforme.

ImmunoCellular Therapeutics, in collaboration with Clinical Cell and Vaccine Production Facility at the University of Pennsylvania, has developed a new method for manufacturing its product candidate, ICT-107, a dendritic cell-based vaccine for the treatment of glioblastoma multiforme (GBM).

ImmunoCellular said that the new method employs a closed-bag system designed to produce highly potent dendritic cells from white blood cells collected from patients, and for subsequently cryopreserving the dendritic cells for future vaccine treatments.

ImmunoCellular claimed that the process may be used to produce 20 or more doses of ICT-107 vaccine from a single blood collection, which may be frozen and later used for vaccination and maintenance of immune response in patients until disease recurrence.

ImmunoCellular Therapeutics president and CEO Manish Singh said that the validated method they have optimised for producing 20 or more doses of dendritic cell-based vaccine from a single blood collection presents cost and convenience advantages over current manufacturing methods, as patients should be able to be treated for several years from a single manufacturing run.

"For example, Provenge, another dendritic cell-based vaccine approved for prostate cancer, is manufactured one dose at a time, contributing to its expensive treatment cost," Singh said.

"We continue to conduct analyses on the per-dose manufacturing-cost savings of this new method as we prepare to initiate a Phase II study of ICT-107 in GBM in the fourth quarter of this year."

Show Hide image

We're hiring! Join the New Statesman as an editorial assistant

The NS is looking for a new recruit.

The New Statesman is hiring an editorial assistant, who will work across the website and magazine to help the office run smoothly. The ideal candidate will have excellent language skills, a passion for journalism, and the ability to work quickly and confidently under pressure.

The job is a broad one – you will need to understand the requirements of both halves of the magazine (politics and culture) as well as having an interest in the technical requirements of magazine and website production. Experience with podcasts and social media would be helpful.

The right person will have omnivorous reading habits and the ability to assimilate new topics at speed. You will be expected to help out with administration tasks around the office, so you must be willing to take direction and get involved with unglamorous tasks. There will be opportunities to write, but this will not form the main part of the job. (Our current editorial assistant is now moving on to a writing post.)

This is a full-time paid job, which would suit a recent graduate or someone who is looking for an entry into journalism. On the job training and help with career development will be offered.

Please apply with an email to Stephen Bush (Stephen. Bush @ with the subject line ‘Editorial Assistant application’.  

In your covering letter, please include a 300-word analysis of the strengths and weaknesses of the New Statesman. Please also include 500 words on what you consider to be the most interesting trend in British politics, and your CV as a Word document. 

The deadline for applications is noon on Monday 12th October.